Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Angiodynamics (ANGO) Shares Repurchased (2017 - 2024)

Angiodynamics' Shares Repurchased history spans 3 years, with the latest figure at $1.1 million for Q4 2024.

For Q4 2024, Shares Repurchased changed N/A year-over-year to $1.1 million; the TTM value through Aug 2025 reached $1.1 million, up 102.54%, while the annual FY2025 figure was $1.7 million, N/A changed from the prior year.
Shares Repurchased reached $1.1 million in Q4 2024 per ANGO's latest filing, up from $552000.0 in the prior quarter.
In the past five years, Shares Repurchased ranged from a high of $1.1 million in Q4 2024 to a low of $552000.0 in Q3 2024.